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Metformin as a biguanid drug entered to the market 50 years ago and now is generally recommended as the
first-line treatment in type 2 diabetes, especially in overweight patients, however in recent years new indications for
its use have emerged . It improves peripheral and liver sensitivity to insulin, reduces basal hepatic glucose
production, increases insulin-stimulated uptake and utilization of glucose by peripheral tissues, decreases hunger and
causes weight reduction.Recently, much attention has been made toward the possible kidney protective efficacy of
metformin. Recent studies have proven that metformin, possesses antioxidant properties, too.Dear Editor-in-Chief,
Metformin as a biguanid drug entered to the market
50 years ago and now is generally recommended as the
first-line treatment in type 2 diabetes, especially in
overweight patients, however in recent years new indi-
cations for its use have emerged [1-3]. It improves per-
ipheral and liver sensitivity to insulin, reduces basal
hepatic glucose production, increases insulin-stimulated
uptake and utilization of glucose by peripheral tissues,
decreases hunger and causes weight reduction [1,3,4].
Recently, much attention has been made toward the
possible kidney protective efficacy of metformin. Recent
studies have proven that metformin, possesses antioxidant
properties, too [1,5]. Reduction of apoptosis, induced by
oxidative stress, in endothelial cells and prevention of vas-
cular dysfunction was found with metformin treatment
[1,5,6]. Previously Morales et al. showed that gentamicin-
induced renal tubular damage is attenuated by metformin
[7]. To better evaluate the ameliorative effect of metformin
against gentamicin tubular toxicity, we conducted a study
on male Wistar rats [8]. In this study, we found, the pre-
ventive property of metformin on gentamicin-induced
acute kidney injury. Hence, it might be beneficial in pa-
tients under treatment with this drug [8]. Recently, Taheri
et al., found, the ameliorative property of metformin
against unilateral ischemia–reperfusion induced injury in
rats [9], which is in accord with our findings. More re-
cently, to test the efficacy of co-administration of garlic ex-
tract and metformin for prevention of gentamicin–renalCorrespondence: hamidnasri@med.mui.ac.ir
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reproduction in any medium, provided the ortoxicity in Wistar rats, we conducted another study on 70
male rats [10]. The result of this study indicates that met-
formin and garlic or their combination has both curative
and protective effects against gentamicin nephrotoxicity.
Hence, garlic extract could safely be used together with
metformin to increase the antioxidant potency to amelior-
ate gentamicin-tubular toxicity [10]. The well-known en-
zyme, AMP-activated kinase (AMPK), is associated with
the pleiotropic actions of metformin [11]. This enzyme reg-
ulates cellular and organ metabolism [5,6,11]. AMPK is a
phylogenetically conserved serine/threonine protein kinase
imagined as a fuel gauge monitoring systemic and cellular
energy condition [5,6,11] and plays an important role in
protecting cellular functions under energy-restricted cir-
cumstances [5,6,11]. Various data indicates that AMPK
activation by metformin is secondary to its effect on the
mitochondria as the primary target of this agent [5,6,11].
Recent findings have revealed the mitochondrial effects
of metformin [5,6,11,12]. Indeed, there is evidence that,
when it is used alone, the advantageous effect of metfor-
min may be due to its mild inhibition of the mitochon-
drial respiratory chain [5,6,11,12]. It is also evident that
metformin treatment, significantly attenuates the increase
in malondialdehyde and total reactive oxygen species gen-
eration and restores the decrease in both enzymatic and
non-enzymatic antioxidants [5], thus, poses the ameliora-
tive effects against toxic effects to the renal tubules
[6,11-14], as we observed in the mentioned studies. How-
ever, the main question is, whether these experimental
findings are applicable in clinical studies. We are mostly
unanimous to use metformin as a first-line glucose-
lowering agent [14-19]. However, it cannot be given to a
proportion of patients with type 2 diabetes due to variousis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lactic acidosis [1,2,16,17]. Scientists emphasize that it must
be used with caution in estimated glomerular filtration
rates of below 60 mL/minute and discontinued when esti-
mated glomerular filtration rate is less than 30 mL/minute
[1,2,16,17]. Metformin-associated lactic acidosis is a severe
metabolic disorder with high mortality and in severe cases
patients may need renal replacement therapy [19]. How-
ever, risk of metformin-associated lactic acidosis could be
decreased by avoiding metformin use in patients with high
risk of sepsis, renal impairment, hypovolemia, reduced kid-
ney capacity such as old age patients [19]. Nevertheless, in
these conditions, metformin may indeed act as an 'inno-
cent bystander' [1,2,16,17,19]. A recent review by Papanas
et al. remarking on the relationship between metformin
and cardiac insufficiency revealed that metformin might
even reduce the risk of cardiac failure morbidity and mor-
tality in diabetics [20]. To find the advantage of adjunct
metformin and insulin therapy in the management of gly-
cemia in critically ill patients, Mojtahedzadeh et al. studied
thirty three traumatized adult patients who were admitted
to the hospital. Patients were randomly assigned to receive
one of three protocols including intensive insulin mono-
therapy (A), metformin monotherapy (B), and intensive in-
sulin therapy in combination with metformin (C) to
maintain blood glucose level between 80–120 mg/dl. They
found that metformin was able to reduce insulin require-
ments in glycemic management of critically ill patients in-
dependent of its plasma concentration. They concluded
that metformin was effective to reverse insulin resistance
without induction of lactic acidosis [21]. On the other
hand, it is possible that the use of metformin would be
favorable in many with chronic renal failure according to
the advantages linked with lessening of metabolic syn-
drome and cardiovascular protection. The actuality of se-
vere metformin-induced lactic acidosis in the absence of
chronic kidney failure raises the question of limitation of
its use in these patients [16,20]. Diabetic nephropathy is
one of the most important complications of diabetes
mellitus [22-26] and metformin has been widely used for
the treatment of type 2 diabetes [17-19]. Kim et al.
conducted a study using metformin for spontaneously dia-
betic rats for 17 weeks. They found that treatment of dia-
betic rats with metformin restored podocyte loss. They
suggested that diabetes-induced podocyte loss in diabetic
nephropathy could be suppressed by metformin, through
the repression of oxidative injury [27]. Thus according to
our results and those published by previous investigators,
metformin protects against tubular injury by restoring the
biochemical alterations and modulation of oxidative stress
on the tubules. Furthermore, according to the study of
Kim et al., metformin protects podocytes in diabetic ne-
phropathy. While in diabetic nephropathy, there is also
tubular cell injury [28-31] due to glycosuria. These findingscan more potentiate the clinical use of metformin in the
prevention of diabetic nephropathy [32-36]. In this re-
gard, to understand the metformin kidney protective
properties better, more experimental rat model or clin-
ical studies are suggested.
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